iPS and ES Cells: Do Both Roads Lead to Rome?
Valerie Y.Ng, Andre B.H.Choo*
Identifiers and Pagination:Year: 2010
First Page: 8
Last Page: 17
Publisher Id: TOSCJ-2-8
Article History:Received Date: 6/07/2009
Revision Received Date: 2/06/2010
Acceptance Date: 7/06/2010
Electronic publication date: 11/10/2010
Collection year: 2010
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The seminal report from Takahashi and Yamanka in 2006 describing the reprogramming of somatic cells to induced pluripotent stem (iPS) cells  marked the beginning of a new field of research, resulting in hundreds of publications in a short 3 years. Among other things, the promise of iPS cells in cell therapy circumvents many of the ethical concerns associated with embryonic stem (ES) cell research, and autologous patient-specific cells can be generated. Nonetheless, the jury is still out on the extent to which iPS cells and ES cells are functionally equivalent. This review focuses on the genetic and functional comparisons between these two cells types.